12. Oct 2026
Description
(AWP Alliance News) - Idorsia highlighted new post hoc analyses from its pivotal Phase 3 PRECISION trial of aprocitentan in resistant hypertension that were already presented at the American Heart Association Hypertension Scientific Sessions 2026. The analyses showed the drug delivered consistent, clinically meaningful blood-pressure reductions in patients with obesity and across earlier and more advanced cardiovascular-kidney-metabolic stages. The company also pointed to signals of kidney benefit, with improvements in albuminuria and stable renal function over longer-term treatment.
Safety findings were broadly consistent across the subgroups, supporting the endothelin pathway as a potential differentiated target in difficult-to-control hypertension.
http://www.globenewswire.com/newsroom/news.html?d=1001277316
Disclaimer: This news brief was created using generative artificial intelligence. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire on October 12, 2026, and is solely responsible for the information contained therein.
